Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.

Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.

<h4>Background</h4>The combination of JAK/STAT and HDAC inhibitors exerted beneficial effects in haematological malignancies, presenting promising therapeutic CTCL targets. We aim to investigate the efficacy of JAK1/2i ruxolitinib in combination with HDACi resminostat in CTCL in vitro.&l...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fani Karagianni, Christina Piperi, Vassiliki Mpakou, Aris Spathis, Periklis G Foukas, Maria Dalamaga, Vasiliki Pappa, Evangelia Papadavid
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/0dc85252357a474f8d023cd0dc50c91a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares